CVQ reports Phase II CVT-E002 data

CV Technologies (CDNX:CVQ) said that in a placebo-controlled Phase II trial of its CVT-E002 immune stimulant in 198 patients, 1% of the treated group versus 7% of the placebo group contracted laborato...